SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-23-004098
Filing Date
2023-05-12
Accepted
2023-05-12 16:20:06
Documents
2
Period of Report
2023-05-10

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 4047
2 MARK AVAGLIANO POA JUL 2019 markavagliano_poa2019.txt EX-24 3356
  Complete submission text file 0001562180-23-004098.txt   8956
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Issuer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 79 T.W. ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709
Business Address
Avagliano Mark (Reporting) CIK: 0001783503 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38096 | Film No.: 23916084